Bill Ackman made nearly nearly $170 million in one day in a Valeant two-day rally. His comment on Valeant Pharmaceutical showed his capability as a remarkable hedge fund manager.
Following Valeant Pharmaceuticals' meltdown, S&P rating service puts Pershing Square Holdings Ltd on review. However, S&P acknowledged swift decision by the firm to strengthen its liquidity after a massive loss.
A huge slump in Valeant Pharmaceutical stocks on Tuesday made Pershing Capital to lose more than $1 billion in one day. Meanwhile Bill Ackman planned to take more active role in the drugmaker.
The Canadian drugmaker on Wednesday announced to add three new directors to its board. Representative from Pershing Square Capital Management was added as one of the directors.
The billionaire investor Mr. Ackman's Pershing Square Capital Management was one of the largest stock holders of Valeant Pharmaceuticals. Ackman has perceptively made his position in Valeant far more important by raising its stake from 5.7% to 9.9% recently. Now, Pershing is the second largest shareholder in Valeant followed by Sequoia Fund led by Ruane, Goldfarb and Cuniff.
The global stock markets turmoil in August and China's economy slowdown have impacted hedge fund mogul William Ackman, who was one of the best performers in 2014. Ackman's Pershing Square Capital Management's Pershing Square LP fund dropped 7.7 percent in August making the total gain during the year at 0.06 percent flat growth.
Billionaire investor William Ackman has purchased a five percent stake in Valeant Pharmaceuticals (VRX.TO) (VRX.N), his hedge fund said on Monday, making him the Canadian drug company's fifth-largest stakeholder.
Botox maker Allergan Inc (AGN.N), fighting a hostile takeover bid by Valeant Pharmaceuticals Inc (VRX.TO), said on Monday it was approached about a potential transaction by another party, identified as Actavis Plc (ACT.N) by a source familiar with the situation.
Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) on Monday said in a letter to Allergan Inc's (AGN.N) board of directors that it was prepared to raise its offer to at least $200 per share but stopped short of doing so.
Herbalife Ltd, the marketer of weight-management products, energy drinks and nutrition supplements that has come under investigation by the Federal Trade Commission as well as other agencies, has hired a former FTC official as its chief compliance officer.
Prominent investor shareholder advisory firm ISS called on Allergan Inc to give its shareholders a chance to vote on any large, buyout-blocking acquisitions and said the company's board faced a credibility problem, according to a report seen by Reuters.
Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec. 18, when activist investor Bill Ackman, who supports a hostile bid for the company by Valeant Pharmaceuticals Inc, will attempt to oust most of its board.
Investors owning 31 percent of shares of Allergan Inc have asked the company to call a special shareholder meeting, activist shareholder William Ackman said on Friday, giving the hedge fund manager a victory in his fight to acquire the Botox maker.
The US Federal Trade Commission has begun an inquiry into the operations of nutrition and weight loss firm Herbalife, an inquiry that has long been asked for by activist investor William Ackman, Reuters reported.
A regulatory filing with the US Securities and Exchange Commission showed that William Ackman's Pershing Square Capital Management offloaded 7.3 million shares of liquor maker Beam Inc this week, Reuters reported.